We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Lactobacillus Farciminis and Hyperalgesia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00852865
Recruitment Status : Completed
First Posted : February 27, 2009
Last Update Posted : May 1, 2009
Information provided by:
Lallemand SAS

February 25, 2009
February 27, 2009
May 1, 2009
February 2009
April 2009   (Final data collection date for primary outcome measure)
Measurement of the mchanical pain threshold in primary and secondary areas by using a punctate stimulus.
Same as current
Complete list of historical versions of study NCT00852865 on ClinicalTrials.gov Archive Site
Measurement of cutaneous temperature of hyperalgesia areas
Same as current
Not Provided
Not Provided
Lactobacillus Farciminis and Hyperalgesia
Effect of a Dialy Consumption of a Probiotic (Lactobacillus Farciminis) on Hyperalgesia in Response to Thermal Stimulation
We want to analyse a possible effect of o dialy consumption of Lactobacillus farciminis on a hyperalgesia on response to thermal stimulation. A comparaison of results before and after three weeks of treatment will be made.
Not Provided
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
  • Inflammation
  • Pain
  • Drug: Lactobacillus farciminis
    1 capsule per day. Each capsule containing 4*109 CFU
  • Drug: Placebo
    1 capsule per day
  • Experimental: 1
    24 healthy volunteers consuming L.farciminis during three weeks
    Intervention: Drug: Lactobacillus farciminis
  • Placebo Comparator: 2
    24 healthy volunteers consuming placebo during three weeks
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
April 2009
April 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • healthy volunteers

Exclusion Criteria:

  • consumption of yogurts
Sexes Eligible for Study: All
18 Years to 60 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
HN 08-17
Not Provided
Not Provided
Lallemand SAS
Not Provided
Principal Investigator: Claude DUBRAY, Professor CPC/CIC-INSERM 501
Lallemand SAS
April 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP